(ABBV) - AbbVie continues major sell-off Rova

a -25% decline in stock value in the past 3 weeks.... very very scary

 

Rick finally got his college degree


April Fools

 

AbbVie Inc
NYSE: ABBV - Apr 3,
$89.54 USD -$1.78 (1.95%)
OMG FIRE RICK !!!

 

If ABBV closes below $90, which is current floor support >>> Next level of support is $70.
YIKES

 

Heavy insider trading occurred in the 8 weeks before Rova T data was made public. C Suite knew about bad data since mid January. The SEC should look into this matter. Abbvie is viewed as untrustworthy in the eyes of the street and investors. The insider trading is still continuing at accelerated pace. The corporate leeched sense disaster and rightfully so. Theyre cashing out and unfortunately, laughing all the way to the bank.

 

SVP in Human Resources Tim R. dumped 87,000 shares in mid December? Hmmmmm

 

You knew too and profited hr guy. lol

 

YIKES !!!! ABBV market cap has fallen $36 billion since Rova T Lie was uncovered.
Stemcentryx duped Ricky into buying a $5.8 billion Edsel. Including market cap loss and bad decision on Stemcentryx, Rick flushed $41.8 BILLION of shareholders $$ down the drain.
Word is this is Ricks last year here. Ready to retire before he's booted and 2018 salary is slashed by 40%. Please leave NOW !!!!!!

 

All hands on deck. Man the lifeboats. Captain Gonzales is hiding while the ships going down. Mayday Mayday

AbbVie Inc
NYSE: ABBV
85.87 USD −2.10 (2.39%)

 

These are staggering and mind blowing numbers. The market cap loss as of today, combined with Stemcentryx bust is now over $50+ Billion.

 

And today's news about flushing $245 million down the toilet to Galopagos for cystic fibrosis drugs with bad data. AppVie's reported hope is to make a combination drug. My hope is that the combination of everyone in the C-Suite is escorted out before they lose all of our money.

 

Why the hell is Abbvie assuming full development and commercial responsibility over this failed investigational program, along with the clinical and preclinical compounds? So Galapagos gets future milestones and royalties, and holds the rights to future development of GLPG-2737 in non-CF indications? Rick gives $45 million upfront and $200 million in milestones? Bottom line, a 3 percent mean increase in ppFEV1 and a mean decrease from baseline in sweat chloride concentration of approximately 25 mmol/L is NOT what the street wants. Street wants at LEAST a 5 percent mean increase in ppFEV1.

 

Rick messed up again.

 

What in the hell are we paying Gosebruch for? Top gun from JP Morgan comes here to broker a potential Abbvie acquisition deal? He brokers Forest Labs sale to Actavis (Allergan) Merck's Cubist takeover but CANT grab any buyers for Abbvie? This bum got his foot in the door from the failed Shire deal which tanked because of Obamas and DOJ inversion laws. He’s performing like crap here and needs to go. Pharma isn’t JP Morgan.Henry needs his ass fired.

 

He needs to go.

 

Will J.P. Morgan take him back?

 

Henry is not the problem.

 

All in due time my friend.

 

Phase III data shows that Rova is outright dangerous!!!
It’s statistically proven to accelerate death.
Who the hell evuauluated the clinical data before we shelled out billions?
Stocks down on this final data. A nail in the coffin of a big fat blunder by Rick.